GlobeNewswire

Novo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and care
11/11/2026
Bagsværd, Denmark, 11 November 2026 – Novo Nordisk today announced a USD 200 million commitment to the World Diabetes Foundation (WDF) for 2027–2036. Announced ahead of World Diabetes Day (14 November), the funding will [...]
Devia Emerges from Stealth with an Agentic AI for GxP Pharma Quality Management
11/11/2026
After a year of building with manufacturing and quality teams, Devia spins out of Visium and is now available to the world’s largest biopharma companies, CDMOs and CROs, so every deviation gets solved once, not closed [...]
Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London
11/11/2026
Leiden, the Netherlands, November 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in London, United Kingdom, on November [...]
Onco-Innovations Announces Agreement to Terminate Performance-Based Funding Arrangement with Sorbie
11/11/2026
VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Onco-Innovations Limited (CBOE: ONCO ) (“ Onco ” or the “ Company ”) announces that it has entered into a termination agreement (the “ Termination Agreement [...]
Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
11/11/2026
MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the pricing of its previously announced underwritten public offering of its common stock, comprised of 18, [...]
Prime Medicine Announces Pricing of Public Offering of Common Stock
11/11/2026
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies
11/11/2026
SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new [...]
U.S. News & World Report Names Over 100 Independently Operating Ensign Group Affiliates Among Best Nursing Homes for 2027
11/11/2026
SAN JUAN CAPISTRANO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), which invests in facilities that provide skilled nursing and senior living services, physical, occupational and [...]
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
10/11/2026
Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 Major BLA amendment added two-year open-label extension (OLE) HOPE-3 [...]
Bionano Reports Third Quarter 2026 Results and Provides a Business Update
10/11/2026
Conference call today, November 10, 2026, at 4:30 PM ET SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2026 [...]
Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
10/11/2026
FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A MGX-001 is designed to deliver durable, endogenous Factor VIII (FVIII) activity from a one-time treatment for [...]
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
10/11/2026
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
10/11/2026
Completed enrollment in the Phase II COVALENT-211 clinical trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes (“T2D”); topline data expected in the first quarter of 2027 Enrollment ongoing in [...]
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
10/11/2026
Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing S-4 Declared Effective by SEC; Stockholder Vote Scheduled for December 9, [...]
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
10/11/2026
A majority-owned and controlled subsidiary of Fortress entered into an agreement with Cedars-Sinai to license FB-607, which is currently being evaluated in an ongoing Phase 2 study for IBS-D MIAMI, Nov. 10, 2026 (GLOBE [...]
Glass House Brands to Host Third Quarter 2026 Earnings Call on November 16, 2026
10/11/2026
LONG BEACH, Calif. and TORONTO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (NYSE: GLAS), one of the fastest-growing cannabis companies in the U.S., [...]
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
10/11/2026
SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the genetics of the [...]
Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance
10/11/2026
REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for [...]
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
10/11/2026
52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LIONHEART-HCM oHCM [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum